AU2021102566A4 - Co-production process of pyruvic acid and Levodopa and use thereof - Google Patents
Co-production process of pyruvic acid and Levodopa and use thereof Download PDFInfo
- Publication number
- AU2021102566A4 AU2021102566A4 AU2021102566A AU2021102566A AU2021102566A4 AU 2021102566 A4 AU2021102566 A4 AU 2021102566A4 AU 2021102566 A AU2021102566 A AU 2021102566A AU 2021102566 A AU2021102566 A AU 2021102566A AU 2021102566 A4 AU2021102566 A4 AU 2021102566A4
- Authority
- AU
- Australia
- Prior art keywords
- pyruvic acid
- catechol
- fermentation
- levodopa
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 title claims abstract description 107
- 229940107700 pyruvic acid Drugs 0.000 title claims abstract description 52
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 38
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960004502 levodopa Drugs 0.000 title claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000855 fermentation Methods 0.000 claims abstract description 36
- 230000004151 fermentation Effects 0.000 claims abstract description 35
- 108091000100 Tyrosine Phenol-Lyase Proteins 0.000 claims abstract description 24
- 239000000758 substrate Substances 0.000 claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960001484 edetic acid Drugs 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 239000011541 reaction mixture Substances 0.000 claims abstract description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 4
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 4
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 4
- 239000000919 ceramic Substances 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 4
- 239000000049 pigment Substances 0.000 claims abstract description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 4
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 4
- 238000007789 sealing Methods 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 11
- 239000002054 inoculum Substances 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000012527 feed solution Substances 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- 239000006137 Luria-Bertani broth Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 235000010216 calcium carbonate Nutrition 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000012137 tryptone Substances 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- WFYHDHNXBXNRNK-UHFFFAOYSA-N 3-hydroxy-5-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]methyl]-2-methylpyridine-4-carboxylic acid Chemical compound CC1=NC=C(CP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(C(O)=O)=C1O WFYHDHNXBXNRNK-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 claims description 2
- 230000004907 flux Effects 0.000 claims description 2
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 241000222126 [Candida] glabrata Species 0.000 abstract description 3
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 239000012141 concentrate Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 8
- 229940076788 pyruvate Drugs 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YTRMTPPVNRALON-UHFFFAOYSA-N 2-phenyl-4-quinolinecarboxylic acid Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=CC=C1 YTRMTPPVNRALON-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 1
- 241000190539 Acremonium rutilum Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241001480003 Chaetothyriales Species 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000901842 Escherichia coli W Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MNXSNBWJLVPGGM-HHWAHKQESA-L Isoniazid calcium pyruvate Chemical compound [Ca+2].[O-]C(=O)C(/C)=N/NC(=O)C1=CC=NC=C1.[O-]C(=O)C(/C)=N/NC(=O)C1=CC=NC=C1 MNXSNBWJLVPGGM-HHWAHKQESA-L 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 235000008540 Mucuna pruriens var utilis Nutrition 0.000 description 1
- 244000003220 Mucuna pruriens var. utilis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002468 cinchophen Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HBMCQTHGYMTCOF-UHFFFAOYSA-N hydroquinone monoacetate Natural products CC(=O)OC1=CC=C(O)C=C1 HBMCQTHGYMTCOF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
- C12P13/225—Tyrosine; 3,4-Dihydroxyphenylalanine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/99—Other Carbon-Carbon Lyases (1.4.99)
- C12Y401/99002—Tyrosine phenol-lyase (4.1.99.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/88—Torulopsis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
OF THE DISCLOSURE
The present disclosure relates to a co-production process of pyruvic acid and levodopa and use
thereof. The following technical solution is adopted: step 1, fermenting Torulopsis glabrata to obtain
a pyruvic acid fermentation broth, removing cell from the fermentation broth by a ceramic membrane,
removing proteins, nucleic acids, pigments and other macromolecules through an ultrafiltration
membrane, and concentrating a resulting filtrate to a pyruvic acid concentration of 150-300 g/L; step
2, preparing the enzyme-catalyzed substrate solution by adding a certain amount of pyruvic acid
concentrated solution, catechol, ammonium acetate, ethylene diamine tetraacetic acid (EDTA), and
sodium sulfite to a resulting pyruvic acid concentrate to adjust to pH 7.0-9.0, and formulating into an;
step 3, using genetically engineered tyrosine phenol lyase (TPL) strain fermentation to obtain a TPL
bacterial suspension, centrifuging to collect cells, breaking cells on a high-pressure homogenizer,
centrifuging, and collecting an enzyme extract; and step 4, adding a certain amount of substrate
solution to the enzyme extract, stirring well, sealing at 25°C, and reacting under shaking. The
substrate solution is prepared by the pyruvic acid concentrate, catechol concentration is controlled at
0-10 g/L by feeding the substrate solution, when a product reaches above 120 g/L, stop feeding the
substrate solution, and when the content of catechol in the reaction mixture is less than 0.2 g/L, stop
the reaction.
Description
[01] The present disclosure relates to a co-production process of pyruvic acid and levodopa and use thereof, and belongs to the field of fermentation and enzyme catalytic processes.
[02] The chemical name of levodopa (L-DOPA) is 3,4-dihydroxyphenylalanine, and the structural formula thereof is:
[03] H0
[04] As an important bioactive substance, L-DOPA is an important intermediate in the biochemical metabolic pathway from L-tyrosine to catechol or melanin.
[05] In the 1960s, a plurality of international scholars had begun on studies of microbial enzymatic synthesis of L-DOPA. In order to improve the yield and substrate conversion rate of L-DOPA, researchers conducted a plurality of studies on the process of microbial enzymatic synthesis of L DOPA.
[061 Tyrosine phenol lyase (TPL, E.C. 4.1.99.2) is a tetrameric enzyme with a molecular weight of about 200 kDa. TPL uses pyridoxal-phosphate (PLP) as a coenzyme. TPL can catalyze the p elimination of L-tyrosine to produce phenol, pyruvic acid, and ammonia. Since this reaction is reversible, after catechol is substituted for phenol, L-DOPA can be produced from catechol, pyruvic acid and ammonia under the catalysis of TPL. The precursor of levodopa inhibits the enzyme activity at higher concentrations. In addition to strong inhibition, catechol and pyruvate can cause irreversible inactivation of the enzyme, so that the reaction conditions are difficult to control, leading to more by products and low yield of L-DOPA.
[07] R. Krishnaveni, Vandana Rathod, et al. from India used the fungus Acremonium rutilum to transform L-tyrosine to L-DOPA with a tyrosinase specific activity of 1,095 U/mg. However, the current production capacity is as low as 0.89 g/L only.
[08] Ikram-Ul-Haq et al. from Pakistan performed UV mutagenesis on Aspergillus oryzae producing tyrosinase, and the maximum yield of mutant strain was 1.28 g/L.
[09] Doaa A. R. Mahmoud and Magda A. El Bendary from Egypt used the tyrosinase of Egyptian halophilic black yeast to produce L-DOPA with a yield of 66 [g/ml.
[10] When Korean researchers used tyrosinase as a catalytic agent, they used electro-substituted reducing reagents to reduce DOPA quinone to L-DOPA, resulting in a conversion rate of 95.9 and an enhanced productivity of 47.27 mg/L*h.
[11] Some researchers used natural bacteria, such as Escherichia,Proteus, Stizolobium hassjoo, and Erwinia, to synthesize L-DOPA, for example, a review of levodopa enzymatic synthesis reported that genetically engineered Escherichiacoli strain expressing TPL could produce 29.6 g/L L-DOPA in 30 h. As another example, Jang-Young Lee et al. cloned p-hydroxyphenylacetate 3-hydroxylase (PHAH) from Escherichiacoli W (ATCC 11105) and converted L-tyrosine to L-DOPA. The product could be accumulated to 10 g/L. The researchers found that although the expression level of TPL was higher in these recombinant strains than in wild strains, the final L-DOPA synthetic ability was not significantly improved or even lower than that of wild strains. In order to obtain the higher L-DOPA synthetic ability, in addition to the high activity of TPL, the strain with better substrate and product transport channels and higher substrate tolerance were also necessary. In general, strict reaction conditions, the unstable TPL enzyme, and plenty of by-products, led to low yield of L-DOPA.
[12] Pyruvic acid is also known as 2-oxopropanoic acid or a-ketopropionic acid. Pyruvic acid is one of the most important organic acids and has a wide range of applications in the fields of pharmaceuticals, food, chemicals, agrochemicals, and scientific research.
[13] Pyruvic acid is used in the pharmaceutical industry for the synthesis of new drugs for the treatment of hypertension, angiotensin II, a series of protease inhibitors, sedatives, anti-inflammatory analgesic cinchophen, medicament phosphoenolpyruvate, 4-metazoline formic acid, antitubercular agent isoniazid calcium pyruvinate, antipyretic 2-phenylquinoline-4-carboxylic acid, and thiadazole drugs.
[14] Pyruvic acid is an important intermediate in the glucose metabolism and synthesis of amino acids and saccharides thereof in vivo. Researchers found that supplementation with pyruvic acid could accelerate the TCA cycle by stimulating mitochondria, thereby accelerating fat consumption for weight loss. Thus, up to 48% of fat is metabolized, and at the same time, the protein loss caused by the low-fat diet can be reduced, and pyruvic acid is highly safe to the human body. In recent years, developed countries have utilized such characteristic of pyruvic acid and calcium salt thereof as a slimming health care medicine.
[15] Industrial production methods of pyruvic acid mainly include chemical synthesis method, enzymatic conversion method, and microbial fermentation method.
[16] Chemical synthesis method:
[17] In 1977, the Japan Research Institute firstly realized the industrialization of the production of pyruvic acid by the chemical synthesis of tartaric acid as raw material. In the liquid or gas phase, tartaric acid (or lactate) is oxidized to pyruvate and hydrolyzed to pyruvic acid, but the method is heavily polluted, high-cost and lack of competitiveness.
[18] Enzymatic conversion method:
[19] Enzyme systems in microbial cells are used for dehydrogenation and oxidation of lactic acid to pyruvic acid. Carsten Schinsche and Helmut Simon found that Proteus vulgaris and Proteus mirabilis could effectively hydrolyze (R)-lactate to produce pyruvic acid; Ping Xu et al. further screened strain KY6 belonging to Edwardisellatarda biogroup 1 from the soil, which could convert DL-lactate to pyruvate. Dariush Hekmat et al. used an enzyme-membrane reactor to convert lactate to pyruvate from a crude extract of Proteus vulgaris cells. This method has high conversion rate but high substrate cost and does not achieve industrial production.
[20] Microbial fermentation method:
Since 1950s, people have begun to explore bio-fermentation way to produce pyruvic acid by the microbes including yeasts, basidiomycetes, actinomycetes, and bacteria. After more than 40 years of research, Japanese scholars have successfully bred strains with high yield of pyruvic acid, and achieved industrialized fermented production in 1989. The level of pyruvic acid production was as high as 67.8 g/L, and the conversion rate was 0.494 g/g. The fermentation method has the following advantages: the method can use sustainable and low-cost glucose as main raw material, can obtain high production and yield, is environmentally friendly, and can avoid some by-products, such as H2 0 2 produced by enzymatic reaction. The fermentation method is a promising industrial way for producing pyruvic acid. At present, a plurality of researchers in China are also focus on doveloping the production of pyruvic acid by fermentation, and have accumulated a plurality of research results. LI Yin, CHEN Jian, et al. had reported and bred a TorulopsisglabrataWSH-IP303 strain, which was subjected to fed-batch fermentation in a 2.5 L fermentor for 56 h, and the yield and conversion rate of pyruvate could reach 69.4 g/L and 0.636 g/g, respectively; the strain was subjected to fed-batch fermentation in a 5 L fermentor for 56 h, and pyruvate yield could reach up to 77.8 g/L, with a glucose conversion rate of 0.651 g/g. XU Qinglong, LIU Liming, et al. reported that Torulopsis glabrata CCTCCM 202019 was fermented in a 7 L fermentor by glucose feeding process, after 83 h fermentation, the yield and conversion rate of pyruvate reached 83.1 g/L and 0.621 g/g, respectively.
High pyruvic acid producing strain, TorulopsisglabrataTP19 bred by GAO Nianfaet al. from Tianjin University of Science and Technology, was fermented in a 5 L fermentor for 48 h, resulting in a maximum pyruvate production of 65.1 g/L, a conversion rate of 58.6%, and a production intensity of 1.35 g/L/h. GAO Nianfa et al. subsequently bred Torulopsis glabrataTP204, the yield of pyruvate in the 5 L fermenter could reach 71.23 g/L. JIANG Ning, WANG Qinhong, et al. from the Institute of Microbiology, Chinese Academy of Sciences bred Torulopsis glabrata IF0005-36, which was fermented in a 5 L fermentor for 52 h, with a pyruvate yield of 82.2 g/L.
[21] Preferred embodiments of the present invention seek to co-produce pyruvic acid by fermentation and levodopa by enzyme catalysis. The pyruvic acid after crude purification is used for production of levodopa under the catalysis of tyrosine phenol lyase (TPL), reducing the cost of levodopa production.
[22] To this end, the present disclosure adopts the following technical solution:
[23] step 1, using Torulopsis glabrata fermentation to obtain a pyruvic acid fermentation broth, removing the cell from the fermentation broth by a ceramic membrane, removing proteins, nucleic acids, pigments through an ultrafiltration membrane, and concentrating a resulting filtrate to a pyruvic acid concentration of 150-300 g/L;
[24] step 2, preparing the enzyme-catalyzed substrate solution by adding a certain amount of catechol, ammonium acetate, ethylene diamine tetraacetic acid (EDTA), and sodium sulfite into the concentrated pyruvic acid solution, and adjusting pH to 7.0-9.0;
[25] step 3, fermenting genetically engineered Escherichiacoli strain expressing tyrosine phenol lyase (TPL) to obtain a TPL bacterial suspension, centrifuging to collect cells, breaking cells on a high-pressure homogenizer, centrifuging, and collecting cell extract as enzyme solution; and
[26] step 4, adding a certain amount of substrate solution to the cell extract, sealing and stirring at °C; where catechol concentration in reaction solution is controlled at 0-10 g/L by feeding the feed solution, and the product reaches above 120 g/L.
[27] Stop feeding the feed solution; when the content of catechol in the reaction mixture is less than 0.2 g/L, the reaction is ended.
[28] The present disclosure has the following beneficial effects: By directly using a crude extract of pyruvic acid fermentation broth as a TPL-catalyzed substrate, the present disclosure may reduce raw material costs and the three wastes (waste gas, waste water, and industrial residue), and have the application value of industrial production.
[29] The present disclosure will be further described below with reference to examples.
[30] Example 1: Fermentation to obtain pyruvic acid
[31] Activation medium (YPD broth) included: 1% yeast extract paste, 2% peptone, and 2% glucose.
[32] Inoculum medium included: 10% glucose, 3% fish peptone, 0.1% K112 P0 4 , 0.05% MgSO4-7H20, 4 mg/L nicotinic acid, 400 [g/L pyridoxal, 20 g/L biotin, and 4% CaCO3, at pH 5.5.
[33] Fermentation medium included: 10% glucose, 0.1% soy peptone, 0.6% (NH4 ) 2 SO 4 , 0.1% KH 2 PO4 , 0.05% MgSO4-7H20, 8 mg/L nicotinic acid, 1 mg/L pyridoxal, 20 [g/L biotin, 20 [g/L thiamine, and 4% CaCO3, at pH 5.5.
[34] Activated culture: A strain stored in a -80°C cryogenic vial was inoculated into a 30 ml threaded-mouth bottle containing 5 ml of YPD broth using a pipette tip, and incubated at 220 r/min and 30°C or 40°C for approximately 12 h, until cells grew to logarithmic phase for transfer culture.
[35] Inoculum culture: The activated bacterial suspension was inoculated into a 500 ml shake flask containing a certain volume (10, 15, and 25 ml) of inoculum medium, and cultured at 220 r/min and °C or 40°C for 24 h.
[36] Fermentation culture: The inoculum fermentation broth was transferred to 500 ml shake flasks containing a certain volume (10, 15, and 25 ml) of fermentation medium at an inoculum size of 10%, and cultured at 220 r/min and 30°C and 40°C for 0-48 h, respectively.
[37] Fermentor fermentation: 15% glucose was added without CaCO3, and other components were the same as those of fermentation medium. The pH was adjusted to 5.5 with 5 M NaOH, rotational speed and oxygen flux were set at 500 and 1:1; without controlling the dissolved oxygen, fermentation was conducted at the corresponding temperature; after culturing for 50-72 h, the fermentation was stopped until pyruvic acid reached above 75 g/L and the product no longer increased.
[38] Crude extraction of pyruvic acid: The fermentation broth passed through a ceramic membrane to remove cells, and the filtrate passed through an ultrafiltration membrane to remove macromolecules such as proteins, nucleic acids, and pigments to obtain an aqueous solution of crude pyruvic acid. The pyruvic acid solution was diluted to 12 g/L, and other substrates were added to prepare a substrate solution; the pyruvic acid solution was concentrated to 120 g/L through a reverse osmosis membrane, and substrates such as catechol were added to prepare a feed solution.
[39] Example 2: Fermentation to produce TPL
[40] LB broth included: 10 g/L tryptone, 0.5 g/L yeast extract, 10 g/L sodium chloride, and pure water.
[41] Fermentation medium included: 12 g/L tryptone, 24 g/L yeast extract, 5 g/L glycerol, 2.31 g/L potassium dihydrogen phosphate, 16.43 g/L dipotassium hydrogen phosphate trihydrate, and pure water.
[42] 1) A single colony was picked and inoculated into a test tube with 4 ml of LB broth supplemented with kanamycin (50 mg/L), and cultured at 37°C and 220 rpm for 12 h to obtain primary inoculum;
[43] 2) The primary inoculum was inoculated into a 100 ml shake flask with fermentation medium, cultured at 37°C and 220 rpm for 4 h, mixed with isopropyl-p-D-thiogalactoside (IPTG) to a final concentration of 1 mM, and cultured at 25°C and 220 rpm for 12 h;
[44] 3) The bacterial suspension in step (2) was centrifuged to collect cells, and the cells were stored in a refrigerator at -20°C.
[45] Example 3: Extraction of TPL
[46] 1) The cells were mixed with 3 times the volume of water, and broken in a high-pressure homogenizer;
[47] 2) A supernatant enzyme extract was obtained by high speed centrifugation;
[48] Example 4: Catalytic reaction of TPL to produce L-DOPA
[49] 1) 0.5 L substrate solution: Crude extraction of pyruvic acid was diluted to a pyruvic acid concentration of 12 g/L; 10 g/L catechol, 60 g/L ammonium acetate, 2 g/L sodium sulfite, and 1 g/L EDTA were added to adjust to pH 8.0;
[50] 2) 0.5 L feed solution: After membrane filtration, the fermented pyruvic acid was concentrated to 120 g/L through a reverse osmosis membrane, and catechol was added to 120 g/L.
[51] 3) 10-100 g of enzyme extract was added to 0.5 L of substrate solution, mixed with pyridoxal triphosphate to 100 mg/L, sealed and stirred at 25°C;
[52] 4) The feed solution was added, and the concentrations of two substrates were controlled at not higher than 10 g/L;
[53] 5) When the product concentration reached above 120 g/L, feeding of feed solution was stopped;
[54] 6) When residual concentration of catechol was less than 0.2 g/L, the reaction was stopped, and L-DOPA concentration would accumulated to over 130 g/L.
[55] 7) The reaction mixture was acidified with dilute sulfuric acid or dilute hydrochloric acid to dissolve crystallized L-DOPA; the cells were removed by centrifugation, and L -DOPA in resulting supernatant was crystallized by adding dilute aqueous ammonia; crystals were collected by centrifugation;
[56] 8) The crude crystals were recrystallized once to obtain the pure L-DOPA product.
[57] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[58] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Claims (5)
1. A co-production process of pyruvic acid and levodopa, comprising the following steps: step 1, fermenting Torulopsis glabratato obtain a pyruvic acid fermentation broth, removing the cell from the fermentation broth by a ceramic membrane, removing proteins, nucleic acids, pigments through an ultrafiltration membrane, and concentrating a resulting filtrate to a pyruvic acid concentration of 150-300 g/L; step 2, preparing the enzyme-catalyzed substrate solution by adding a certain amount of pyruvic acid concentrated solution, catechol, ammonium acetate, ethylene diamine tetraacetic acid (EDTA), and sodium sulfite and adjusting pH to 7.0-9.0; step 3, fermenting genetically engineered Escherichiacoli strain expressing tyrosine phenol lyase (TPL) , centrifuging to collect cells, breaking cells on a high-pressure homogenizer, recentrifuging, and collecting cell extract containing TPL enzyme; and step 4, adding a certain amount of substrate solution to the cell extract, sealing and stirring at 25°C; wherein catechol concentration in the reaction solution is controlled at 0-10 g/L by feeding the feed solution, when a product reaches above 120 g/L, feeding of the feed solution is stopped, and when the content of catechol in the reaction mixture is less than 0.2 g/L, the reaction is ended.
2. The co-production process of pyruvic acid and levodopa according to claim 1, wherein a fermentor fermentation process in step 1 is as follows: adding 15% glucose without CaCO3, and other components being the same as those of fermentation medium; adjusting pH to 5.5 with 5 M NaOH, setting rotational speed at 500 and oxygen flux at 1 vvm; without controlling the dissolved oxygen, fermenting at the corresponding temperature for 50-72 h, and stopping the fermentation until the pyruvic acid reaches above 75 g/L and the product no longer increases.
3. The co-production process of pyruvic acid and levodopa according to claim 1, wherein in step 3, Luria-Bertani (LB) broth comprises: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium chloride, and pure water; the fermentation medium comprises: 12 g/L tryptone, 24 g/L yeast extract, 5 g/L glycerol, 2.31 g/L potassium dihydrogen phosphate, 16.43 g/L dipotassium hydrogen phosphate trihydrate, and pure water.
4. The co-production process of pyruvic acid and levodopa according to claim 3, wherein a single colony is picked and inoculated into a test tube with 4 ml of LB broth supplemented with kanamycin
(50 mg/L), and cultured at 37°C and 220 rpm for 12 h to obtain a primary inoculum; the primary inoculum is inoculated into a 100 ml shake flask with fermentation medium, cultivated at 37°C and 220 rpm for 4 h, adding isopropyl-p-D-thiogalactoside (IPTG) to a final concentration of 1 mM, and continued to incubate at 25°C and 220 rpm for 12 h; the cells was collected by centrifugation and stored in a refrigerator at -20°C.
5. The co-production process of pyruvic acid and levodopa according to claim 4, wherein the TPL enzyme is prepared by breaking cells with 3 times volume of water in a high-pressure homogenizer; a supernatant cell extract is obtained by high speed centrifugation;
wherein in the step 4, 10-100 g of the enzyme extract is added to 0.5 L of the substrate solution, mixed with pyridoxal triphosphate to 100 mg/L, sealed and stirred at 25°C;
wherein in step 4, when residual concentration of catechol is less than 0.2 g/L, the reaction is stopped, and levodopa concentration is accumulated to above 130 g/L; the reaction mixture is acidified with dilute sulfuric acid or dilute hydrochloric acid to dissolve crystals; the cells are removed by centrifugation, and L-DOPA in resulting supernatant is crystallized by adding dilute aqueous ammonia; crystals of L-DOPA are collected by centrifugation, and crude crystals are recrystallized once by acid dissolution and alkaline precipitation to obtain the pure product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021102566A AU2021102566A4 (en) | 2021-05-14 | 2021-05-14 | Co-production process of pyruvic acid and Levodopa and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021102566A AU2021102566A4 (en) | 2021-05-14 | 2021-05-14 | Co-production process of pyruvic acid and Levodopa and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021102566A4 true AU2021102566A4 (en) | 2021-07-01 |
Family
ID=76584669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021102566A Ceased AU2021102566A4 (en) | 2021-05-14 | 2021-05-14 | Co-production process of pyruvic acid and Levodopa and use thereof |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021102566A4 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113788763A (en) * | 2021-10-26 | 2021-12-14 | 四川大学 | Method for synthesizing levodopa and derivatives thereof based on bionic hydroxylation system |
-
2021
- 2021-05-14 AU AU2021102566A patent/AU2021102566A4/en not_active Ceased
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113788763A (en) * | 2021-10-26 | 2021-12-14 | 四川大学 | Method for synthesizing levodopa and derivatives thereof based on bionic hydroxylation system |
CN113788763B (en) * | 2021-10-26 | 2023-08-15 | 四川大学 | Method for synthesizing levodopa based on bionic hydroxylation system |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3550026B1 (en) | L-isoleucine-producing corynebacterium glutamicum fermentation medium and culture method | |
US20100297715A1 (en) | Method for producing succinic acid | |
Cheng et al. | Production of 1, 3-propanediol by Klebsiella pneumoniae from glycerol broth | |
WO2017080111A1 (en) | Genetically-engineered bacteria for producing cadaverine and method thereof for preparing cadaverine | |
CN110055292B (en) | Pyruvic acid and levodopa co-production process and application | |
AU2021102566A4 (en) | Co-production process of pyruvic acid and Levodopa and use thereof | |
CN111187794B (en) | Method for preparing L-phenylalanine by using escherichia coli fermentation | |
CN103243128B (en) | High-yield production method of GABA (gamma amino butyric acid) through mixed fermentation of brevibacterium tianjinese and lactobacillus plantarum | |
NL2028307B1 (en) | Co-production process of pyruvic acid and levodopa and use thereof | |
CN104531810A (en) | Method for preparing maltonic acid through efficient microbial conversion | |
CN112708645A (en) | Method for efficiently producing monosodium glutamate | |
CN110698536A (en) | Novel method for producing glutathione by adopting fermentation method | |
CN110564789B (en) | Method for producing L-theanine by using escherichia coli fermentation | |
CN101054597A (en) | Method for producing cystine by microorganism transformation | |
CN112430633A (en) | Process for producing arginine by using fed-batch culture solution for fermentation | |
CN110923275A (en) | Fermentation and extraction process of glutamic acid | |
CN114277065B (en) | Method for co-production of lactic acid and succinic acid by mixed fermentation | |
CN112662609B (en) | Fermentation medium for increasing yield of beta-alanine and application method | |
CN111424061B (en) | Rhodococcus ruber and method for producing nicotinamide by using same | |
RU2712703C1 (en) | Method of producing lactic acid | |
CN116445559B (en) | Production method of glutamic acid independent gamma-polyglutamic acid | |
CN114606276B (en) | Method for improving fermentation yield of L-threonine | |
CN116004740A (en) | Method for producing L-citrulline | |
CN115216504A (en) | Fermentation conversion method of salidroside | |
CN117512024A (en) | Application of acetate in promoting biological fermentation to prepare lactic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |